患有炎症性肠道疾病的患者在从参考产品阿达利穆马布 (adalimumab) 转换为生物类似的阿达利穆马布-阿托托 (adalimumab-atto) 时的看法
Catherine Pham1, Deana Bitar2, Fang Niu1
1Pharmacy Outcomes Research Group, Kaiser Permanente National Pharmacy, Downey, CA, USA.
Expert opinion on biological therapy
|April 1, 2025
概括
患有炎症性肠病 (IBD) 的患者转换为阿达利穆马布-阿托生物类似药,对安全性,有效性和成本表示满意. 然而,许多人认为他们对生物类似药缺乏足够的知识,这表明需要更好地教育患者.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 患者对切换到生物类似药物的担忧存在.
- 阿达利穆马布是一种用于炎症性肠病 (IBD) 的生物疗法.
研究的目的:
- 描述患者从参考产品 (RP) 转换为阿达利穆马布 (adalimumab-atto) 后的患者前景.
- 评估患者对生物类似剂阿达利穆马布-阿托的满意度和担忧.
主要方法:
- 在美国成年IBD患者中进行了一项电话调查.
- 调查了在100天内从RP阿达利慕姆巴切换到阿达利慕姆巴-阿托的患者.
- 收集的数据包括安全性,有效性,成本,产品偏好和接受的教育.
主要成果:
- 大多数患者 (77.9%) 报告说,他们对疾病控制,副作用或转换后的成本没有担忧.
- 28.7%的人更喜欢阿达利穆马布-阿托,而39.3%的人没有偏好.
- 患者对教育的满意度中等 (43.7%),65.1%的人认为他们缺乏足够的知识.
结论:
- 在切换到阿达利穆马布-阿托托后,观察到广泛的患者满意度.
- 患者报告说,他们对阿达利穆马布-阿托的知识有限,这凸显了需要改善患者对生物类似药的教育.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
109
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
109
Drugs for Treatment of Ulcerative Colitis in IBD
110
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
110
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
259
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
259
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91


